Sponsors:
This program is jointly sponsored by the University of Michigan Medical School and IMPACt, Inc.
Commercial Support:
This activity is supported by educational grants from Genentech BioOncology and Pfizer.
Description:
"Virtual Renal Cell Tumor Board" is a case-based discussion highlighting current issues and changing dynamics in the treatment of renal cell carcinoma. The panel of experts discuss the most appropriate management options for the cases and emphasize a multidisciplinary team approach to treatment.
Learning Objectives:
Upon completion of this activity, participants will be able to:
1. Describe the diagnostic evaluation of patients with renal cell cancer
2. Cite evidence-based therapy recommendations for the cases presented
3. Review modern multidisciplinary treatment options and outcomes for renal cell cancer patients including the use of novel targeted agents
4. Describe the evolving role of neoadjuvant systemic therapy
5. Describe appropriate front line therapies for metastatic RCC
6. Describe research into 2nd line treatment options for TKI refractory patients
7. Review the integration of surgery and systemic therapy in the treatment of patients with metastatic renal cell carcinoma
Target Audience:
This activity has been designed to meet the educational needs of medical oncologists and urologists involved in the care of patients with renal cell carcinoma.
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and IMPACT, Inc. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
The University of Michigan Medical School designates this activity for a maximum of 1 AMA PRA Category 1 credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Agenda:
This program will be 60 minutes in length. The multidisciplinary panel of experts will discuss cases that highlight current issues in the management of renal cell carcinoma including:
1. Locally advanced RCC
- What is the potential role of targeted therapy? (on-going adjuvant clinical trials)
2. Metastatic RCC (Clear cell)
- Role of biopsy
- Standard of care
- Choice of agents
- Role of neoadjuvant therapy
- Timing of surgery
- Role of cytoreductive surgery
- Surgical management of residual disease
- Relapse, TKI Refractory
3. Poor risk/unresectable mRCC
- When is cytoreduction contraindicated?
- Treatment options for poor risk disease
- Impact of targeted therapy on primary tumor downstaging
Faculty:
Christopher G. Wood, MD, FACS (Course Director)
Associate Professor
Urology and Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Eric Jonasch, MD
Assistant Professor
Genitourinary Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Surena F. Matin, M.D., FACS
Associate Professor of Urology
Medical Director, Minimally Invasive New Technology in Oncologic Surgery (MINTOS)
The University of Texas M. D. Anderson Cancer Center
CME Content Reviewer
Samuel M. Silver, MD, PhD
Professor and Associate Dean for Research
University of Michigan Medical School
Director, University of Michigan
Cancer Center Network
University of Michigan Healthcare Network
Disclosure of Conflicts of Interest:
Faculty Disclosure Statements:
The University of Michigan Medical School endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the Association of American Medical Colleges that the sponsors of continuing medical education activities and the speakers at these activities disclose significant relationships with commercial companies whose products are discussed in educational presentations. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Significant relationships exist with the following companies whose products will be discussed.
Eric Jonasch, MD
Consultant: Bayer Onyx, Genentech and Pfizer
Speaker’s Bureau: Bayer Onyx, Novartis and Wyeth
Grant/ Research: Genentech and Pfizer
Surena Matin, MD, FACS
Speaker’s Bureau: Ethicon Wound Management
Christopher Wood, MD
Consultant: Antigenics, Inc.
Speaker’s Bureau: Pfizer
Grant/Research: National Institutes of Health
Samuel M. Silver, MD, PhD
Consultant: Blue Cross Blue Shield of Michigan
Grant/Research: Blue Cross Blue Shield of Michigan